Designing and Developing Suppository Formulations for anti-HIV Drug Delivery

References

• History of the Suppository Form . AiacheJMRenouxRFistreD ( Eds). J.R. Prous Publishers, Barcelona, Spain (1984).
   Google Scholar
• Shah SM Sultan AH Thakar R . The history and evolution of pessaries for pelvic organ prolapse. Int. Urogynecol. J. Pelvic Floor Dysfunct.17 (2), 170–175 (2006).
   PubMed Web of Science ®Google Scholar
• FDA. U.S. Food and Drug Administration: Rectal Drugs. 2017(03–01). www.fda.gov.
   Google Scholar
• FDA. U.S. Food and Drug Administration: Vaginal Drugs. 2017(4/20). www.fda.gov.
   Google Scholar
• Jannin V Lemagnen G Gueroult P Larrouture D Tuleu C . Rectal route in the 21st Century to treat children. Adv. Drug. Deliv. Re.v73, 34–49 (2014).
   PubMed Web of Science ®Google Scholar
• Pharmacopoeia E . European Directorate for the Quality of Medicines and Healthcare. Rectal Preparations EP 01/2008:1145 (2011).
   Google Scholar
• Pharmacopoeia US . The U.S. Pharmacopoeia. Nomenclature Guidlines <1121>36 (2016).
   Google Scholar
• Pharmacopoeia J . The Japanese Pharmacopoeia: 17th Edition. Monogrpahs for Preparations18–19 (2016).
   Google Scholar
• Ham AS Ugaonkar SR Shi L et al. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J. Pharm. Sci.101 (4), 1423–1435 (2012).
   PubMed Web of Science ®Google Scholar
• Dezzutti CS Rohan LC Wang L et al. Reformulated tenofovir gel for use as a dual compartment microbicide. J. Antimicrob. Chemother.67 (9), 2139–2142 (2012).
   PubMed Web of Science ®Google Scholar
• Rohan LC Moncla BJ Kunjara Na Ayudhya RP et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE5 (2), e9310 (2010).
   PubMed Web of Science ®Google Scholar
• Akil A Parniak M Dezzutti C et al. Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv. Transl. Res.1 (3), 209–222 (2011).
   PubMed Web of Science ®Google Scholar
• Gupta KM Pearce SM Poursaid AE et al. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci.97 (10), 4228–4239 (2008).
   PubMed Web of Science ®Google Scholar
• Ham AS Rohan LC Boczar A Yang L Buckheit K Buckheit RW Jr . Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm. Res. (2012).
   PubMed Web of Science ®Google Scholar
• Ham AS Nugent ST Peters JJ et al. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. Antiviral. Res.120, 153–164 (2015).
   PubMed Web of Science ®Google Scholar
• Dezzutti CS Yandura S Wang L et al. Pharmacodynamic activity of dapivirine and maraviroc single entity and combination topical gels for HIV-1 prevention. Pharm. Res.32 (11), 3768–3781 (2015).
   PubMed Web of Science ®Google Scholar
• Das Neves J Martins JP Sarmento B . Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing. Adv. Drug. Deliv. Rev.103, 20–32 (2016).
   PubMed Web of Science ®Google Scholar
• Naicker N Naidoo A Werner L et al. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials. Antivir. Ther. (2016).
   PubMed Web of Science ®Google Scholar
• Pereira LE Mesquita PM Ham A et al. Pharmacokinetic and pharmacodynamic evaluation following vaginal application of IQB3002, a dual-chamber microbicide gel containing the nonnucleoside reverse transcriptase inhibitor IQP-0528 in Rhesus macaques. Antimicrob. Agents. Chemother.60 (3), 1393–1400 (2015).
   PubMed Web of Science ®Google Scholar
• Marrazzo JM Ramjee G Richardson BA et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med.372 (6), 509–518 (2015).
   PubMed Web of Science ®Google Scholar
• Rees H Delany-Moretlwe S Baron D et al. FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. CROI (2015).
   Google Scholar
• Abdool Karim Q Abdool Karim SS Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science329 (5996), 1168–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Van Der Straten A Stadler J Montgomery E et al. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE9 (2), e89118 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang W Hu M Shi Y et al. Vaginal microbicide film combinations of two reverse transcriptase inhibitors, EFdA and CSIC, for the prevention of HIV-1 sexual transmission. Pharm. Res.32 (9), 2960–2972 (2015).
   PubMed Web of Science ®Google Scholar
• Grammen C Van Den Mooter G Appeltans B et al. Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. Int. J. Pharm.475 (1–2), 238–244 (2014).
   PubMedGoogle Scholar
• Peitzmeier SM Tomko C Wingo E et al. Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city. AIDS Care1–5 (2017).
   Web of Science ®Google Scholar
• Clark JT Clark MR Shelke NB et al. Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS ONE9 (3), e88509 (2014).
   PubMed Web of Science ®Google Scholar
• Baeten JM Palanee-Phillips T Brown ER et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N. Engl. J. Med.375 (22), 2121–2132 (2016).
   PubMed Web of Science ®Google Scholar
• Pines HA Gorbach PM Weiss RE et al. Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial. AIDS Behav.17 (3), 1002–1015 (2013).
   PubMed Web of Science ®Google Scholar
• Newman PA Cameron MP Roungprakhon S Tepjan S Scarpa R . Acceptability and preferences for hypothetical rectal microbicides among a community sample of young men who have sex with men and transgender women in Thailand: a discrete choice experiment. AIDS Behav.20 (11), 2588–2601 (2016).
   PubMed Web of Science ®Google Scholar
• Vargas SE Fava JL Severy L et al. Psychometric properties and validity of a multi-dimensional risk perception scale developed in the context of a microbicide acceptability study. Arch. Sex. Behav.45 (2), 415–428 (2016).
   PubMed Web of Science ®Google Scholar
• Weld ED Hiruy H Guthrie KM et al. A comparative pre-Phase I study of the impact of gel vehicle volume on distal colon distribution, user experience, and acceptability. AIDS. Res. Hum. Retroviruses (33 (5), 440–447 (2016).
   PubMed Web of Science ®Google Scholar
• Morrow KM Underhill K Van Den Berg JJ Vargas S Rosen RK Katz DF . User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides. Arch. Sex. Behav.43 (7), 1459–1467 (2014).
   PubMed Web of Science ®Google Scholar
• Morrow K Ruiz M . Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav.12 (2), 272–283 (2008).
   PubMed Web of Science ®Google Scholar
• Exner TM Correale J Carballo–Diéguez A et al. Women's anal sex practices: implications for formulation and promotion of a rectal microbicide. AIDS Education and Prevention20 (2), 148–159 (2008).
   PubMed Web of Science ®Google Scholar
• Mcgowan I Dezzutti C . Rectal microbicide development. Curr. Top. Microbiol. Immunol.383, 117–136 (2014).
   PubMed Web of Science ®Google Scholar
• Gorbach PM Weiss RE Fuchs E et al. The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk. Sex. Transm. Dis.39 (1), 59–64 (2012).
   PubMed Web of Science ®Google Scholar
• Mcgowan I . Rectal microbicides: can we make them and will people use them?AIDS Behav.15 (0), 66–71 (2011).
   Google Scholar
• Abd-El-Maeboud KH El-Naggar T El-Hawi EMM Mahmoud SaR Abd-El-Hay S . Rectal suppository: commonsense and mode of insertion. Lancet338 (8770), 798–800 (1999).
   Google Scholar
• Bradshaw A Price L . Rectal suppository insertion: the reliability of the evidence as a basis for nursing practice. J. Clin. Nurs.16 (1), 98–103 (2007).
   PubMed Web of Science ®Google Scholar
• Saleem MA Taher M Sanaullah S et al. Formulation and evaluation of tramadol hydrochloride rectal suppositories. Indian. J. Pharm. Sci.70 (5), 640–644 (2008).
   PubMed Web of Science ®Google Scholar
• Wada K Uehara S Ishii A et al. A Phase II clinical trial evaluating the preventive effectiveness of lactobacillus vaginal suppositories in patients with recurrent cystitis. Acta. Med. Okayama70 (4), 299–302 (2016).
   PubMed Web of Science ®Google Scholar
• Naz S Memon NY Sattar A Baloch R . Diclofenac rectal suppository: an effective modality for perineal pain. J. Pak. Med. Assoc.66 (8), 1005–1008 (2016).
   PubMed Web of Science ®Google Scholar
• Ye X Yin H Lu Y Zhang H Wang H . Evaluation of hydrogel suppositories for delivery of 5-aminolevulinic acid and hematoporphyrin monomethyl ether to rectal tumors. Molecules21 (10), (2016).
   Web of Science ®Google Scholar
• Verdenelli MC Cecchini C Coman MM et al. Impact of probiotic SYNBIO® administered by vaginal suppositories in promoting vaginal health of apparently healthy women. Curr. Microbiol.73 (4), 483–490 (2016).
   PubMed Web of Science ®Google Scholar
• Lowry M . Rectal drug administration in adults: how, when, why. Nurs. Times.112 (8), 12–14 (2016).
   Google Scholar
• Li B Zaveri T Ziegler GR Hayes JE . Shape of vaginal suppositories affects willingness-to-try and preference. Antiviral. Res.97 (3), 280–284 (2013).
   PubMed Web of Science ®Google Scholar
• Morrow KM Hendrix C . Clinical evaluation of microbicide formulations. Antiviral Res.88, Supplement(0), S40–S46 (2010).
   PubMed Web of Science ®Google Scholar
• Morrow K Rosen R Richter L et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a Phase I clinical trial. J. Women's Health12 (7), 655–666 (2003).
   PubMed Web of Science ®Google Scholar
• Whitehead SJ Kilmarx PH Blanchard K et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS20 (17), 2141–2148 (2006).
   PubMed Web of Science ®Google Scholar
• Mahan ED Morrow KM Hayes JE . Quantitative perceptual differences among over-the-counter vaginal products using a standardized methodology: implications for microbicide development. Contraception84 (2), 184–193 (2011).
   PubMed Web of Science ®Google Scholar
• Moreton RC . Suppository Bases, Hard Fat. Pharmaceutical Press, PA, USA, 945–950 (2012).
   Google Scholar
• Brown JM Hess KL Brown S Murphy C Waldman AL Hezareh M . Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States. Obstet. Gynecol.121 (4), 773–780 (2013).
   PubMed Web of Science ®Google Scholar
• Porter TL Stewart R Reed J Morton K . Models of hydrogel swelling with applications to hydration sensing. Sensors (Basel, Switzerland)7 (9), 1980–1991 (2007).
   PubMed Web of Science ®Google Scholar
• Wu CY Benet LZ . Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res.22 (1), 11–23 (2005).
   PubMed Web of Science ®Google Scholar
• Lane T Pettifor A Pascoe S Fiamma A Rees H . Heterosexual anal intercourse increases risk of HIV infection amoung young South African men. AIDS20 (1), 123–125 (2006).
   PubMed Web of Science ®Google Scholar
• Buckheit RW Jr Roberson JL Lackman-Smith C Wyatt JR Vickers TA Ecker DJ . Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses10 (11), 1497–1506 (1994).
   PubMed Web of Science ®Google Scholar
• Buckheit R Jr Watson K Morrow K Ham A . Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res.85, 142–158 (2010).
   PubMed Web of Science ®Google Scholar
• Zaveri T Hayes JE Ziegler GR . Release of tenofovir from carrageenan-based vaginal suppositories. Pharmaceutics6 (3), 366–377 (2014).
   PubMedGoogle Scholar
• Zhang G Zhang H Yu H Zhao Z Yang J Zhang M . Hypothetical rectal microbicide acceptability and factors influencing it among men who have sex with men in Tianjin, China. PLoS ONE11 (5), e0156561 (2016).
   PubMed Web of Science ®Google Scholar
• Jones DL Weiss SM Chitalu N Bwalya V Villar O . Acceptability of microbicidal surrogates among Zambian women. J. Sex. Transm. Dis.35 (2), 147–153 (2008).
   PubMed Web of Science ®Google Scholar
• Cranston RD Lama JR Richardson BA et al. MTN-017: a rectal Phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel. Clin. Infect. Dis.64 (5), 614–620 (2017).
   PubMed Web of Science ®Google Scholar
• Zaveri T Primrose RJ Surapaneni L Ziegler GR Hayes JE . Firmness perception influences women's preferences for vaginal suppositories. Pharmaceutics6 (3), 512–529 (2014).
   PubMedGoogle Scholar
• Ham AS Nugent ST Beveridge E et al. Designing the suppository: a rational formulation design for rectal and vaginal administration. Presented at : HIV R4P. Chicago, IL, USA, October 17–21, 2016.
   Google Scholar
• Holt BY Morwitz VG Ngo L et al. Microbicide preference among young women in California. J. Women's Health15 (3), 281–294 (2006).
   PubMed Web of Science ®Google Scholar
• Malonza IM Mirembe F Nakabiito C et al. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS (London, England)19 (18), 2157–2163 (2005).
   PubMed Web of Science ®Google Scholar
• Schwartz JL Mauck C Lai JJ et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception74 (2), 133–140 (2006).
   PubMed Web of Science ®Google Scholar
• Cao YJ Caffo BS Fuchs EJ et al. Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging. Br. J. Clin. Pharmacol.74 (6), 1013–1022 (2012).
   PubMed Web of Science ®Google Scholar
• Hendrix CW Fuchs EJ Macura KJ et al. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin. Pharmacol. Ther.83 (1), 97–105 (2008).
   PubMed Web of Science ®Google Scholar
• Yahagi R Machida Y Onishi H . Mucoadhesive suppositories of ramosetron hydrochloride utilizing Carbopol. Int. J. Pharm.193 (2), 205–212 (2000).
   PubMedGoogle Scholar
• Yahagi R Onishi H Machida Y . Preparation and evaluation of double-phased mucoadhesive suppositories of lidocaine utilizing Carbopol and white beeswax. J. Control. Rel.61 (1–2), 1–8 (1999).
   PubMed Web of Science ®Google Scholar
• Kawashima S Inoue Y Shimeno T Fujiwara H . Studies on sustained-release suppositories. III. Rectal absorption of morphine in rabbits and prolongation of its absorption by alginic acid addition. Chem. Pharm. Bull. (Tokyo)38 (2), 498–505 (1990).
   PubMed Web of Science ®Google Scholar
• Takatori T Shimono N Higaki K Kimura T . Evaluation of sustained release suppositories prepared with fatty base including solid fats with high melting points. Int. J. Pharm.278 (2), 275–282 (2004).
   PubMedGoogle Scholar
• Carpenter CC Cooper DA Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA283 (3), 381–390 (2000).
   PubMed Web of Science ®Google Scholar
• Richman DD . HIV therapeutics. Science272 (5270), 1886–1888 (1996).
   PubMed Web of Science ®Google Scholar
• Trabattoni D Lo Caputo S Biasin M et al. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin. Diagn. Lab. Immunol.9 (5), 1114–1118 (2002).
   PubMedGoogle Scholar